Endocrinology · Pediatrics · Neurology · 7 h ago
FDA Approves Tiratricol for Peripheral Thyrotoxicosis in MCT8 Deficiency
The FDA approved Emcitate (tiratricol) as the first FDA-approved therapy for peripheral thyrotoxicosis in MCT8 deficiency. Evidence came from a randomized, placebo-controlled trial and a longer-term open-label study involving infants through adults; the announcement did not report sample sizes or numerical treatment effects.
- First FDA-approved treatment for peripheral thyrotoxicosis in MCT8 deficiency.
- Evidence included randomized placebo-controlled and longer-term open-label studies.
- FDA reported thyroid hormone reductions and cardiovascular and metabolic improvements.
- Announcement omitted sample sizes and numerical treatment effects.
The FDA approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The rare genetic disorder primarily affects males and impairs thyroid hormone transport into the brain, while excess hormone accumulates in the bloodstream. The approval, granted to Egetis Therapeutics US Inc., is the first FDA approval for treatment of symptoms associated with this condition.
Effectiveness was evaluated in two studies involving infants through adults: an international, multicenter, randomized, placebo-controlled trial (NCT05579327) and a longer-term open-label study. The FDA reported reductions in excess circulating thyroid hormone and improvements in cardiovascular and metabolic symptoms, including systolic blood pressure and heart rate. The announcement did not provide sample sizes, numerical treatment effects or detailed study durations.
Emcitate is administered once daily as a liquid suspension, orally or through a feeding tube. The most common adverse effects were diarrhea, vomiting, rash and excessive sweating. The FDA advised that it should not be used together with another thyroid medication and that patients taking such medication should consult their clinician before starting treatment. The indication addresses peripheral thyrotoxicosis; the announcement did not report evidence of benefit for the disorder’s neurological manifestations.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
U.S. Food and Drug Administration: FDA Approves First Treatment for MCT8 Deficiency ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.